Vivesto is a Swedish speciality pharma company focusing on its proprietary XR-17 and XR-18 technology platforms to develop novel formulations of well-established cytostatic oncology treatments for human and animal health. Key assets include Apealea (partnered with Elevar), docetaxel micellar and Cantrixil.
Vivesto is developing improved formulations of well-established cancer drugs through the application of its proprietary XR-17 and XR-18 platforms. This solubility enhancing technology has received validation though a global partnership deal for lead asset Apealea (Cremophor-free paclitaxel) with Elevar Therapeutics across a variety of cancers. Apealea is approved in Europe for 2nd-line ovarian cancer and will be launched by Inceptua in H222. Additional studies are expected to be required before a US NDA filing. Vivesto is working on additional nanoparticle formulations, including docetaxel micellar (Phase Ib prostate cancer). In-licensed asset Cantrixil is expected to start Phase II development in ovarian cancer. In March, Vivesto completed a rights issue raising gross proceeds of c SEK151m and interim results in August confirmed the company is well capitalised. In July it announced it has wound down its Russian operations and appointed Christer Nordstedt as acting CEO.
Despite a slew of novel cancer drugs transforming care for many oncology indications, established chemotherapy regimens remain a cornerstone of treatment. Vivesto’s XR-17 and XR-18 technology is applicable to any solubility limited drug, which includes 10–15 different cytostatic agents, and can potentially provide an improved formulation and profile.